FDA approval
2007年11月7日 - 4:01PM
RNSを含む英国規制内ニュース (英語)
RNS Number:1561H
Arthro Kinetics plc
07 November 2007
Press Release
Radio Frequency system receives 510(k) US FDA approval
WEDNESDAY, 7th November 2007 - Arthro Kinetics plc (AIM: AKI) ("Arthro
Kinetics"), the orthopedics company dedicated to regenerating joint mobility and
spinal disc function announces that its VESALIUS(R) radio frequency generator
and spinal probe system for soft tissue ablation has received 510(k) approval
from the US Food & Drugs Administration (FDA).
The Arthro Kinetics radio frequency generator and spinal probe system utilizes
the VESALIUS(R) molecular resonance technology allowing the spine surgeon to
easily, accurately and efficiently cut, ablate and seal soft tissue at lower
temperatures minimizing the potential for bleeding, scarring and other damage to
surrounding tissue.
Jason Loveridge, CEO of Arthro Kinetics commented:
"This is excellent news for Arthro Kinetics. Radio frequency technology is a
critical component of endoscopic surgery and this approval enhances
significantly the portfolio of instruments we can now make available to surgeons
in the US".
CONTACTS
Arthro Kinetics Plc Tel: +49 (0)711 305 110 70
Jason Loveridge, Chief Executive Officer
Doug Quinn, Chief Financial Officer
Nomura Code Securities Limited Tel: +44 (0)207 776 1200
Clare Terlouw
END
This information is provided by RNS
The company news service from the London Stock Exchange
END
REAUNUWRBWRARAA
Arthro Kinetics (LSE:AKI)
過去 株価チャート
から 5 2024 まで 6 2024
Arthro Kinetics (LSE:AKI)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Arthro Kinetics (ロンドン証券取引所): 0 recent articles
その他のArthro Kinetics Plcニュース記事